In preclinical research, PNT2258 has shown promising single agent efficacy, combination therapy efficacy and relevant drug-dose response for multiple cancer types including both hematological and solid tumors.
ProNAi has partnered with Novosom and Polymun to develop liposome-based technologies to deliver the company’s unique DNAi oligonucleotides. The company has also partnered with New York-based Foundation Ventures, an investment banking firm that will assist in coordinating ProNAi’s upcoming fundraising efforts in support of DNAi and PNT2258.
Robert Forgey, acting CEO of ProNAi, said: “This is an important milestone in developing therapies to treat diseases via the novel class of nucleic acid drugs represented by DNAi. We have kept pace with RNAi-based approaches and are utilizing a novel, potentially breakthrough technology, to safely and effectively administer PNT2258.”